35 / 40
Relapsed platinum sensitive ovarian,
fallopian tube, primary peritoneal
cancer
Arm 1
Chemotherapy +
cediranib
daily x 6 c followed
by
maintenance cediranib (daily) plus olaparib
Arm 2:
Chemotherapy +
cediranib
(5:2) x 6 c
followed by
maintenance cediranib (5:2) plus placebo
Stratified by 6-12 vs >12 month progression free interval; BRCA status;
surgery vs no surgery at relapse prior to chemotherapy; prior bevacizumab
Cediranib: 20 mg OD
(daily vs 5 days on/ 2 days off-5:2)
Olaparib: 300 mg BD
Combination of PARPi and antiangiogenic
ICON 9: TFIp > 6 months